TNFRSF4 and cancer: We further demonstrated that high PRKCI expression in PDAC is associated with reduced activation of several immune signaling pathways implicated in the improved survival of PDAC cancer patients, including OX40, iCOS, and Th1 signaling [84,85,86,87].